476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1
作者
Igor Bondarenko,John A. Glaspy,Adam Brufsky,Oleg Nikolaevich Lipatov,Edith A. Perez,Stephen Y.T. Chan,X. Zou,See-Chun Phan,Nicholas J. Robert,Veronique C Dieras